Have a personal or library account? Click to login
A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes Cover

A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes

Open Access
|Oct 2019

References

  1. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26(Suppl 5): v116-25. doi: 10.1093/annonc/mdv304
  2. Fisher RI, Miller TP, O’Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004; 221-36. doi: 10.1182/asheducation-2004.1.221
  3. Bush RS, Gospodarowicz M, Sturgeon J, Alison R. Radiation therapy of localized non-Hodgkin’s lymphoma. Cancer Treat Rep 1977; 61: 1129-36. PMID: 332347
  4. Haque W, Dabaja B, Tann A, Khan M, Szeja S, Butler EB, et al. Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after rituximab: a population-based analysis. Radiother Oncol 2016; 120: 150-5. doi: 10.1016/j.radonc.2016.05.027
  5. Vargo JA, Gill BS, Balasubramani GK, Beriwal S. Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: do we still need consolidative radiotherapy? J Clin Oncol 2015; 33: 3710-7. doi: 10.1200/JCO.2015.61.7654
  6. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42. doi: 10.1056/NEJMoa011795
  7. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12: 1013-22. doi: 10.1016/S1470-2045(11)70235-2
  8. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010; 28: 4170-6. doi: 10.1200/JCO.2009.27.3441
  9. Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 2014; 32: 1112-8. doi: 10.1200/JCO.2013.51.4505
  10. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018; 24: 679-90. doi: 10.1038/s41591-018-0016-8
  11. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11. doi: 10.1038/35000501
  12. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82. doi: 10.1182/blood-2003-05-1545
  13. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-23. doi: 10.1056/NEJMoa0802885
  14. Chong VC, Yap ES, Xin L, Chin ST, Jeyasekharan A, Chee Y-L, et al. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma (DLBCL), and prognostic significance of cell of origin (COO) in a southeast Asian cohort. Blood 2018; 132(Suppl 1): 4222. doi: 10.1182/blood-2018-99-119672
  15. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987-94. doi: 10.1056/NEJM199309303291402
  16. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059-68. doi: 10.1200/JCO.2013.54.8800
  17. Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol 2002; 13(Suppl 1): 79-83. doi: 10.1093/annonc/13.s1.79
  18. Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2014; 89: 49-58. doi: 10.1016/j. ijrobp.2014.01.006
  19. Specht L. Does radiation have a role in advanced stage Hodgkin’s or Non-Hodgkin lymphoma? Curr Treat Options Oncol 2016; 17: 4. doi: 10.1007/s11864-015-0377-x
  20. Horning SJ, Weller E, Kim K, Earle JD, O’Connell MJ, Habermann TM, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22: 3032-8. doi: 10.1200/JCO.2004.06.088
  21. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-205. doi: 10.1056/NEJMoa042040
  22. Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thieblemont C, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007; 25: 787-92. doi: 10.1200/JCO.2006.07.0722
  23. Aviles A, Nambo MJ, Calva A, Neri N, Cleto S, Silva L. Adjuvant radiotherapy in patients with diffuse large B-cell lymphoma in advanced stage (III/IV) improves the outcome in the rituximab era. Hematology 2018; 1-5. doi: 10.1080/10245332.2018.1423880
  24. Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 2018; 131: 174-81. doi: 10.1182/blood-2017-07-793984
  25. Pfreundschuh M, Murawski N, Ziepert M, Altmann B, Dreyling MH, Borchmann P, et al. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. J Clin Oncol 2018; 36(15 Suppl): 7574. doi: 10.1200/JCO.2018.36.15_suppl.7574.
  26. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, et al. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys 2013; 86: 569-77. doi: 10.1016/j.ijrobp.2013.02.007
  27. Fridrik MA. ASCO update on lymphoma. Memo 2017; 10: 218-9. doi: 10.1007/s12254-017-0372-y
  28. Issa DE, van de Schans SA, Chamuleau ME, Karim-Kos HE, Wondergem M, Huijgens PC, et al. Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. Haematologica 2015; 100: 525-33. doi: 10.3324/haematol.2014.107300
DOI: https://doi.org/10.2478/raon-2019-0045 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 473 - 479
Submitted on: Jun 26, 2019
|
Accepted on: Aug 11, 2019
|
Published on: Oct 25, 2019
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2019 Chrishanthi Rajasooriyar, Jeremy Tey, Lea Choung Wong, Michelle Poon, Rao Nandini, Ivan Tham, Balamurugan Vellayappan, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.